BR112020017018A2 - Proteínas de ligação anti-antígeno de mieloma lambda (lma) para tratamento de disordens autoimunes e cânceres que expressem o lma - Google Patents
Proteínas de ligação anti-antígeno de mieloma lambda (lma) para tratamento de disordens autoimunes e cânceres que expressem o lma Download PDFInfo
- Publication number
- BR112020017018A2 BR112020017018A2 BR112020017018-6A BR112020017018A BR112020017018A2 BR 112020017018 A2 BR112020017018 A2 BR 112020017018A2 BR 112020017018 A BR112020017018 A BR 112020017018A BR 112020017018 A2 BR112020017018 A2 BR 112020017018A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- binding protein
- amino acid
- acid sequence
- aml
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018900534A AU2018900534A0 (en) | 2018-02-20 | Composition and method | |
| AU2018900534 | 2018-02-20 | ||
| PCT/AU2019/050137 WO2019161443A1 (en) | 2018-02-20 | 2019-02-20 | Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020017018A2 true BR112020017018A2 (pt) | 2020-12-29 |
Family
ID=67686653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020017018-6A BR112020017018A2 (pt) | 2018-02-20 | 2019-02-20 | Proteínas de ligação anti-antígeno de mieloma lambda (lma) para tratamento de disordens autoimunes e cânceres que expressem o lma |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11447571B2 (https=) |
| EP (1) | EP3755724A4 (https=) |
| JP (2) | JP7490559B2 (https=) |
| KR (1) | KR102824611B1 (https=) |
| CN (1) | CN111918879B (https=) |
| AU (2) | AU2019225446B2 (https=) |
| BR (1) | BR112020017018A2 (https=) |
| CA (1) | CA3091711A1 (https=) |
| SG (1) | SG11202007925SA (https=) |
| WO (1) | WO2019161443A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250326864A1 (en) * | 2022-06-13 | 2025-10-23 | Paradox Immunotherapeutics Inc. | Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass |
| WO2025236034A1 (en) * | 2024-05-13 | 2025-11-20 | HaemaLogiX Ltd | Anti-lma binding proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548921A (en) | 2004-02-27 | 2008-09-26 | Immune System Therapeutics Ltd | Target for B-cell disorders |
| US20100187181A1 (en) * | 2009-01-29 | 2010-07-29 | Sortwell Edwin T | Method for Dispersing and Aggregating Components of Mineral Slurries |
| WO2010115238A1 (en) * | 2009-04-07 | 2010-10-14 | Immune System Therapeutics Ltd | Method for treating immune disorders |
| GB201203938D0 (en) * | 2012-03-06 | 2012-04-18 | Binding Site Group The Ltd | Assay system |
-
2019
- 2019-02-20 BR BR112020017018-6A patent/BR112020017018A2/pt unknown
- 2019-02-20 CN CN201980012636.9A patent/CN111918879B/zh active Active
- 2019-02-20 EP EP19758107.7A patent/EP3755724A4/en active Pending
- 2019-02-20 US US16/970,991 patent/US11447571B2/en active Active
- 2019-02-20 SG SG11202007925SA patent/SG11202007925SA/en unknown
- 2019-02-20 KR KR1020207027033A patent/KR102824611B1/ko active Active
- 2019-02-20 WO PCT/AU2019/050137 patent/WO2019161443A1/en not_active Ceased
- 2019-02-20 CA CA3091711A patent/CA3091711A1/en active Pending
- 2019-02-20 AU AU2019225446A patent/AU2019225446B2/en active Active
- 2019-02-20 JP JP2020544005A patent/JP7490559B2/ja active Active
-
2021
- 2021-04-06 AU AU2021202092A patent/AU2021202092A1/en not_active Abandoned
-
2022
- 2022-08-12 US US17/819,483 patent/US12435158B2/en active Active
-
2024
- 2024-05-15 JP JP2024079382A patent/JP7798956B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3091711A1 (en) | 2019-08-29 |
| EP3755724A1 (en) | 2020-12-30 |
| JP2021514369A (ja) | 2021-06-10 |
| CN111918879A (zh) | 2020-11-10 |
| US20230174675A1 (en) | 2023-06-08 |
| JP2024100838A (ja) | 2024-07-26 |
| CN111918879B (zh) | 2024-10-15 |
| JP7798956B2 (ja) | 2026-01-14 |
| SG11202007925SA (en) | 2020-09-29 |
| US12435158B2 (en) | 2025-10-07 |
| US20210230309A1 (en) | 2021-07-29 |
| WO2019161443A1 (en) | 2019-08-29 |
| EP3755724A4 (en) | 2022-03-23 |
| AU2021202092A1 (en) | 2021-04-29 |
| AU2019225446A1 (en) | 2020-10-08 |
| KR102824611B1 (ko) | 2025-06-24 |
| US11447571B2 (en) | 2022-09-20 |
| KR20210005553A (ko) | 2021-01-14 |
| JP7490559B2 (ja) | 2024-05-27 |
| AU2019225446B2 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12371509B2 (en) | Antibodies specific to MUC18 | |
| US20210221907A1 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
| US12311031B2 (en) | Antibodies specific to CD44 | |
| US12378310B2 (en) | Antibodies specific to folate receptor alpha | |
| ES2811274T3 (es) | Anticuerpos monoclonales humanizados y quiméricos para CD99 | |
| JP7798956B2 (ja) | 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 | |
| CN113423830A (zh) | 对muc18特异性的抗体 | |
| EP4527407A1 (en) | Anti-mesothelin antibodies and uses thereof | |
| CN118271438A (zh) | 抗cgrp抗体或其抗原结合片段及其用途 | |
| HK40061374A (en) | Antibodies specific to cd44 | |
| HK40060752A (en) | Antibodies specific to muc18 | |
| HK40060753A (en) | Antibodies specific to muc18 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |